Between April 13, 2016, and February 8, 2020, 85 patients with ALK-positive advanced NSCLC were screened, while 21 of which were excluded including 16 patients who did not meet inclusion eligibility, 4 patients who withdrew consent, and 1 patient who died after signing the consent. This evidence concerns the gene ALK and non-small cell lung carcinoma.